Tag: Central Nervous System Therapeutics Market – Global Central Nervous System Therapeutics Industry Size

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Central Nervous System Therapeutics Market Revenue Growth On Track For A 8.8% CAGR Through 2030

The market for central nervous system therapeutics has experienced robust expansion over recent years. Its valuation is projected to increase from $134.99 billion in 2025 to $147.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. This historical growth is primarily due to factors such as the escalating prevalence of depression and epilepsy, an expanding elderly demographic, the scarcity of treatment solutions for degenerative conditions, an uptick in hospitalization rates for CNS conditions, and improvements in hospital and clinic facilities.

The central nervous system therapeutics market size is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $206.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This growth throughout the forecast period stems from the advancement of innovative neuroprotective agents, an increase in biologics and gene-based therapies, greater investment in neuroscience research, the increasing acceptance of personalized medicine, and broadened access to CNS treatments in developing markets. Key trends observed during this period encompass the escalating prevalence of neurological and mental health conditions, the increasing use of combination therapies for CNS disorders, a heightened emphasis on managing long-term disease and controlling symptoms, the proliferation of homecare-based CNS treatment options, and enhanced drug formulations designed for improved blood-brain barrier penetration.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=76991238&type=smp&name=Central%20Nervous%20System%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Central Nervous System Therapeutics Market Growth Factors: What’s Supporting Expansion?

The rising incidence of mental health conditions is anticipated to drive the expansion of the central nervous system therapeutics market. Mental health disorders cover a broad spectrum of ailments that impact a person’s thoughts, feelings, conduct, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The escalating occurrence of these disorders is attributed to increased exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics aid in treating mental health disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For example, in December 2025, a report released by Bristol City Council, a UK-based local government authority, indicated that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, showing a 6.0% rise from 2021-22. Consequently, the increasing prevalence of mental health disorders is fueling the growth of the central nervous system therapeutics market.

Central Nervous System Therapeutics Market Segment Performance And Emerging Opportunities

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Central Nervous System Therapeutics Market Industry Trends: What’s Reshaping Demand?

Major companies engaged in the central nervous system therapeutics market are focusing on creating advanced solutions, such as capsid engineering, to improve targeted gene delivery, enhance therapeutic efficacy, and facilitate blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel adeno-associated virus (AAV) for central nervous system (CNS) delivery, employing their proprietary ALIGATER platform. It demonstrated significantly improved transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Notably, expression levels equivalent to AAV9 were attained at just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver, while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

Central Nervous System Therapeutics Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

View The Full Central Nervous System Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Central Nervous System Therapeutics Market Regional Analysis And Leading Geography

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Central Nervous System Therapeutics Market Revenue Outlook: What CAGR Is Expected Through 2030?

The central nervous system therapeutics market has seen robust expansion in recent years. It is projected to rise from $134.99 billion in 2025 to $147.29 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. This historic growth has been driven by factors such as a growing prevalence of depression and epilepsy, an aging population, a scarcity of therapies for degenerative diseases, higher rates of hospitalization for CNS-related conditions, and improved hospital and clinic infrastructure.

The central nervous system therapeutics market is projected to experience significant expansion in the coming years, with an anticipated increase to $206.68 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.8%. This forecasted growth is driven by the emergence of innovative neuroprotective agents, advancements in biologics and gene-based therapies, heightened financial commitments to neuroscience research, a growing emphasis on personalized medicine, and improved accessibility to central nervous system treatments in emerging markets. Key developments shaping this period include the escalating incidence of neurological and mental health conditions, an increased incorporation of combination therapies for managing CNS disorders, a heightened focus on long-term disease management and symptom alleviation, the expansion of home-based treatment options for CNS care, the introduction of enhanced drug formulations designed to more effectively penetrate the blood-brain barrier, and a broader adoption of these solutions across various healthcare settings.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Central Nervous System Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?

The growth of the central nervous system therapeutics market is anticipated to be driven forward by the rising occurrence of mental health disorders. These disorders encompass a broad spectrum of conditions that influence an individual’s thoughts, emotions, behaviors, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. Their increasing prevalence is largely attributed to heightened exposure to chronic stress, which impairs emotional regulation, diminishes coping abilities, and fosters conditions like anxiety, depression, and burnout. Central nervous system (CNS) therapeutics address mental health disorders by acting on brain chemicals and neural circuits responsible for mood, behavior, and cognition. For example, a December 2025 report from Bristol City Council, a UK local government body, revealed that in Bristol, 66,815 patients aged 18 and above were noted on GP practice depression registers during 2022-23, representing a 6.0% increase relative to 2021-22. Hence, the escalating prevalence of mental health disorders is fueling expansion in the central nervous system therapeutics market.

Central Nervous System Therapeutics Market Segment Analysis Highlighting Growth Areas

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Central Nervous System Therapeutics Market Trends Reshaping Industry Growth

Leading firms in the central nervous system therapeutics sector are advancing their efforts through innovations like capsid engineering, which aims to refine targeted gene delivery, boost therapeutic effectiveness, and improve crossing of the blood-brain barrier for better management of neurological conditions. This process involves altering and enhancing the protein shell—often referred to as the capsid—of viral vectors, particularly adeno-associated viruses (AAVs), that play a key role in gene therapy. A notable example from May 2025 is Coave Therapeutics S.A., a biotechnology company based in France, which introduced coAAV CSF 01, a novel AAV vehicle designed specifically for central nervous system (CNS) applications, developed with their proprietary ALIGATER platform. Tests revealed that this vector achieved substantially higher transduction efficiency and safety relative to AAV9. When delivered through intracisternal magna or intracerebroventricular methods, coAAV-CSF-01 produced transgene expression that was 100 times greater in the cortex and 10,000 times more pronounced in the hippocampus at equivalent doses. Interestingly, it matched AAV9’s expression levels while requiring only one-fifth of the dosage, underscoring its enhanced strength. Furthermore, the vector exhibited significantly less off-target activity outside the CNS, particularly in peripheral organs like the liver, and maintained a strong safety record with preserved integrity of peripheral nerves. Findings point to this vector’s capacity to improve CNS gene therapy outcomes, offering greater precision and lowering risks associated with systemic treatments.

Central Nervous System Therapeutics Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Access The Complete Central Nervous System Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Central Nervous System Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Central Nervous System Therapeutics Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The central nervous system therapeutics market has experienced significant expansion in recent years. It is anticipated to increase from $134.99 billion in 2025 to $147.29 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. Historically, this market’s development has been propelled by factors such as the rising prevalence of depression and epilepsy, an expanding aging population, restricted treatment options for degenerative disorders, an increase in hospitalization rates for CNS conditions, and the growth of hospital and clinic infrastructure.

The market for central nervous system therapeutics is projected to experience robust expansion over the coming years. It is anticipated to reach $206.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This anticipated growth during the forecast period is attributable to several factors, including the creation of new neuroprotective agents, an increase in biologics and gene-based therapies, greater investment in neuroscience research, the growing acceptance of personalized medicine, and wider availability of CNS treatments in developing markets. Key trends expected during the forecast period involve the increasing occurrence of neurological and mental health conditions, the expanding use of combination therapies for CNS diseases, a heightened emphasis on managing diseases over the long term and controlling symptoms, the growth of homecare-based CNS treatment options, and enhanced drug formulations that improve blood-brain barrier penetration.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

Which Major Factors Are Contributing To The Development Of The Central Nervous System Therapeutics Market?

The growing incidence of mental health disorders is projected to propel the expansion of the central nervous system therapeutics market. Mental health disorders refer to a broad spectrum of conditions affecting an individual’s thinking, feeling, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The increasing prevalence of these disorders is attributed to greater exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to issues like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics are instrumental in treating mental health disorders by targeting the specific brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, a report from Bristol City Council in December 2025 highlighted that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, marking a 6.0% rise from 2021-22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics market.

How Is The Central Nervous System Therapeutics Market Examined Through Segment Analysis?

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Which Trends Are Expected To Shape The Central Nervous System Therapeutics Market?

Leading companies in the central nervous system therapeutics market are concentrating on developing innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration for more effective treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a biotechnology company based in France, launched coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery, leveraging their proprietary ALIGATER platform. This new vector demonstrated significantly enhanced transduction efficiency and safety when compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

Who Are The Major Companies Operating In The Central Nervous System Therapeutics Market?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Access The Complete Central Nervous System Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Which Region Is The Primary Market For The Central Nervous System Therapeutics Market?

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Central Nervous System Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company

Insurance Business Process Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/insurance-business-process-outsourcing-global-market-report

Outsourced Customer Care Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-customer-care-services-global-market-report

Outsourced Software Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-software-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Central Nervous System Therapeutics Market Expected To Change From 2026 To 2030?

The central nervous system therapeutics market size has seen substantial growth in recent years. It is projected to expand from $134.99 billion in 2025 to $147.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period is attributable to the increasing burden of depression and epilepsy, a growing aging population, the limited treatment options available for degenerative disorders, rising hospitalization rates for cns conditions, and the expansion of hospital and clinic infrastructure.

The central nervous system therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $206.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. The projected growth throughout the forecast period is primarily driven by factors such as the development of novel neuroprotective agents, the expansion of biologics and gene-based therapies, increasing investment in neuroscience research, the rising adoption of personalized medicine, and expanding access to cns treatments in emerging markets. Concurrently, major trends expected during this period include the rising prevalence of neurological and mental health disorders, the growing adoption of combination therapies for cns diseases, an increasing focus on long-term disease management and symptom control, the expansion of homecare-based cns treatment solutions, and improved drug formulations with better blood-brain barrier penetration.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

What Primary Drivers Are Shaping The Central Nervous System Therapeutics Market?

The rising occurrence of mental health conditions is anticipated to fuel the expansion of the central nervous system therapeutics market in the future. These disorders encompass a wide array of conditions that influence an individual’s thinking, feelings, actions, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The growing incidence of mental health problems is attributed to heightened exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to issues like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics are instrumental in treating mental health disorders by targeting brain chemicals and neural pathways essential for mood, behavior, and cognition. For instance, in December 2025, a report published by the Bristol City Council, a UK-based local government authority, highlighted that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, indicating a 6.0% rise from 2021-22. Consequently, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics market.

How Is The Central Nervous System Therapeutics Market Organized By Segment Classification?

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

What Market Trends Are Affecting The Central Nervous System Therapeutics Market?

Key companies within the central nervous system therapeutics market are prioritizing the development of innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for more effective treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), employed in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a French biotechnology company, introduced coAAV CSF 01, a novel adeno associated virus (AAV) designed for central nervous system (CNS) delivery, utilizing their proprietary ALIGATER platform. This new vector demonstrated significantly enhanced transduction efficiency and safety when compared to AAV9. When administered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, expression levels equivalent to AAV9 were attained at merely one-fifth of the dose, highlighting its superior potency. Additionally, the vector exhibited substantially reduced off-target expression in peripheral organs like the liver, while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These outcomes underscore the vector’s potential to enhance CNS gene therapy results with greater precision and reduced systemic risk.

Who Are The Industry Participants Involved In The Central Nervous System Therapeutics Market?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Get The Full Central Nervous System Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Which Region Is The Top Contributor To The Central Nervous System Therapeutics Market By Share?

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Central Nervous System Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company

Insurance Business Process Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/insurance-business-process-outsourcing-global-market-report

Outsourced Customer Care Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-customer-care-services-global-market-report

Outsourced Software Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-software-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Central Nervous System Therapeutics Market From 2026 To 2030?

The central nervous system therapeutics market has experienced significant expansion in recent years. It is projected to increase from $134.99 billion in 2025 to $147.29 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. This historical growth can be attributed to the rising prevalence of depression and epilepsy, an expanding aging demographic, the restricted availability of treatments for degenerative disorders, an uptick in hospitalization rates for CNS conditions, and the development of hospital and clinic infrastructure.

The central nervous system therapeutics market size is projected to undergo significant expansion in the coming years, reaching $206.68 billion by 2030 with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is primarily driven by the development of novel neuroprotective agents, the rise in biologics and gene-based therapies, heightened investment in neuroscience research, the increasing embrace of personalized medicine, and the broader availability of CNS treatments in emerging markets. Noteworthy trends anticipated in this period include the rising incidence of neurological and mental health disorders, a growing adoption of combination therapies for CNS conditions, an increased emphasis on long-term disease management and symptom alleviation, the expansion of homecare-based CNS treatment solutions, and improved drug formulations offering better blood-brain barrier penetration.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

What Major Drivers Are Influencing Demand In The Central Nervous System Therapeutics Market?

The increasing occurrence of mental health conditions is anticipated to stimulate the future growth of the central nervous system therapeutics market. These disorders encompass a broad spectrum of conditions that impact an individual’s thinking, feeling, behavior, or mood, including examples like depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising frequency of mental health disorders is attributed to increased exposure to chronic stress, which can impair emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics aid in treating mental health disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, a report published by the Bristol City Council, a UK-based local government authority, revealed that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, indicating a 6.0% rise from 2021-22. Consequently, the growing prevalence of mental health disorders is propelling the central nervous system therapeutics market’s expansion.

Which Segments Are Included In The Analysis Of The Central Nervous System Therapeutics Market?

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Which Trends Are Impacting The Growth Of The Central Nervous System Therapeutics Market?

Companies operating in the central nervous system therapeutics market are prioritizing innovative solutions like capsid engineering to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, introduced coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery utilizing their proprietary ALIGATER platform. It demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Notably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, underscoring its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results highlight the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

Which Key Industry Participants Are Active In The Central Nervous System Therapeutics Market?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Read the full central nervous system therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Central Nervous System Therapeutics Market?

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Central Nervous System Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company

Insurance Business Process Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/insurance-business-process-outsourcing-global-market-report

Outsourced Customer Care Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-customer-care-services-global-market-report

Outsourced Software Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-software-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the central nervous system therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Central Nervous System Therapeutics Market size between 2026 and 2035?

The central nervous system therapeutics market has experienced significant growth in recent years. It is anticipated to expand from $134.99 billion in 2025 to $147.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. This historic growth can be attributed to several factors, including the increasing burden of depression and epilepsy, an expanding aging population, the limited treatment options available for degenerative disorders, rising hospitalization rates for CNS conditions, and the expansion of hospital and clinic infrastructure.

The central nervous system therapeutics market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $206.68 billion, demonstrating an 8.8% compound annual growth rate (CAGR). This projected growth can be attributed to factors such as the development of innovative neuroprotective agents, the expansion of biologics and gene-based therapies, increased investment in neuroscience research, the growing acceptance of personalized medicine, and wider access to CNS treatments in developing markets. Key trends influencing this period encompass the increasing incidence of neurological and mental health conditions, the greater uptake of combination therapies for CNS ailments, an enhanced emphasis on long-term disease management and symptom regulation, the proliferation of homecare-based CNS treatment options, and advancements in drug formulations to improve blood-brain barrier penetration.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

Which Drivers Are Impacting Market Performance In The Central Nervous System Therapeutics Market?

The future expansion of the central nervous system therapeutics market is anticipated to be driven by the rising incidence of mental health conditions. These disorders encompass various conditions impacting an individual’s thoughts, emotions, actions, or state of mind, including examples like depression, anxiety disorders, schizophrenia, and bipolar disorder. The growth in mental health disorder cases stems from heightened exposure to ongoing stress, which can impair emotional control, diminish coping abilities, and lead to issues such as anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics address mental health conditions by acting on brain chemicals and neural connections that influence mood, behavior, and cognitive functions. As an illustration, in December 2025, a report from the Bristol City Council, a UK-based local government body, indicated that in Bristol, 66,815 patients aged 18 and over were listed on GP practice depression registers during 2022-23, representing a 6.0% increase compared to 2021-22. Consequently, the expanding occurrence of mental health disorders is a key factor propelling the central nervous system therapeutics market forward.

What Segment Types Are Examined In The Central Nervous System Therapeutics Market?

The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes

2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:

1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics

2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents

3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids

4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives

5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief

6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

Which Trends Are Expected To Influence The Central Nervous System Therapeutics Market In The Upcoming Years?

Major companies within the central nervous system therapeutics market are concentrating on developing groundbreaking solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), utilized in gene therapy. As an example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery, leveraging their proprietary ALIGATER platform. This vector showcased significantly enhanced transduction efficiency and safety when compared to AAV9. Administered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at an identical dose. Remarkably, equivalent expression levels to AAV9 were achieved with only one-fifth of the dose, highlighting its superior potency. Additionally, the vector demonstrated substantially reduced off-target expression in peripheral organs, such as the liver, while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes through improved precision and lower systemic risk.

Who Are The Major Companies Operating In The Central Nervous System Therapeutics Market?

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Central Nervous System Therapeutics Market?

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Central Nervous System Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company

Insurance Business Process Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/insurance-business-process-outsourcing-global-market-report

Outsourced Customer Care Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-customer-care-services-global-market-report

Outsourced Software Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/outsourced-software-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model